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ART ICLE Open Ac ce s s
Real-life achievement of lipid-lowering
treatment targets in the DIAbetes and
LifEstyle Cohort Twente: systemic
assessment of pharmacological and
nutritional factors
Christina M. Gant 1,2, S. Heleen Binnenmars1,2, Manon Harmelink1, Sabita S. Soedamah-Muthu3,4, Stephan J. L. Bakker2,
Gerjan Navis2 and Gozewijn D. Laverman1,2
Abstract
Background/Objectives Lowering low-density lipoprotein cholesterol (LDLc) in type 2 diabetes mellitus is of
paramount importance in preventing cardiovascular disease. However, treatment targets for LDLc are often not
reached. We studied the prevalence of LDLc target achievement in a real-life population of type 2 diabetes mellitus
patients in secondary care, and investigated whether in those not on target, there is room for intensifying
pharmacological and lifestyle management according to current treatment guidelines.
Subjects/MethodsWe performed a cross-sectional analysis in the DIAbetes and LifEstyle Cohort Twente-1 (DIALECT-1;
n= 450, age 63 ± 9 years, 58% men, diabetes duration 11 (7–18) years). At baseline, we determined plasma LDLc
concentration, pharmacological treatment (i.e., statin use), and lifestyle (physical activity and dietary intake). Patients
were divided according to LDLc < 1.8, LDLc 1.8–2.5, and LDLc > 2.5 mmol/l. Dietary intake was collected from a
validated Food Frequency Questionnaire (177 items) and we determined guideline adherence for different food
groups. Physical activity was assessed with the Short Questionnaire to ASsess Health enhancing behavior.
Results LDLc data were available in 428 type 2 diabetes mellitus patients. LDLc ≤ 2.5 mmol/l was achieved in 317
patients (76%). In total, 76% of patients used statins, in those with LDLc > 2.5 mmol/l, this was 44%. Adherence to
lifestyle guidelines was not different between the LDLc groups and was as follows: body mass index 6%, physical
activity 59%, vegetables 7%, fruit 28%, legumes 59%, nuts 14%, dairy 19%, ﬁsh 36%, tea 8%, fats 66%, red meat 12%,
processed meat 2%, alcohol 71%, sweetened beverages 34%, and sodium 12%.
Conclusions In type 2 diabetes mellitus patients in secondary health care, the target LDLc is achieved by three
quarters of patients. Increasing statin treatment could be a ﬁrst step to improve LDLc. In addition, there are ample
opportunities for lifestyle management through increasing adherence to lifestyle guidelines.
Introduction
Type 2 diabetes mellitus is associated with a sub-
stantially increased risk for cardiovascular disease (CVD),
of up to two times higher than the general population,
especially if disease duration is > 10 years1, 2. Prevention
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of cardiovascular complications is therefore one of the
main aims in the overall treatment for type 2 diabetes
mellitus, with appropriate treatment of dyslipidemia as
one of the major goals. Lowering of low-density lipopro-
tein cholesterol (LDLc) in type 2 diabetes mellitus con-
sistently reduces cardiovascular events3–6 and every 1.0
mmol/l reduction in LDLc is associated with a corre-
sponding 20–25% reduction in CVD mortality and non-
fatal myocardial infarction7.
Based on the literature, diabetes guidelines have incor-
porated targets for LDLc as well as recommendations for
pharmacological and lifestyle treatment to reach these
targets8, 9. However, several studies show that in clinical
practice, a large proportion (44–67%) of patients with type
2 diabetes mellitus does not achieve the recommended
treatment targets10–12, but an integral understanding of
where opportunities may lie to improve management are
lacking13. Whereas some studies on this subject focus on
pharmacological management and general lifestyle habits
(i.e., body mass index (BMI), smoking, and alcohol), and
others on in-depth nutritional habits14–16, an integral
approach is warranted, because both pharmacological
treatment and dietary composition contribute to clinical
outcomes and are part of clinical management. Previously,
we have shown that for blood pressure management there
are numerous opportunities in lifestyle management17.
In this study, we aim to determine the prevalence of
LDLc target achievement in a real-life population of type
2 diabetes mellitus patients in secondary care, and
investigate whether in those not on target, there is room
for intensifying pharmacological and lifestyle manage-
ment according to current treatment guidelines.
Materials and Methods
We performed a cross-sectional analysis in baseline data
from the DIAbetes and LifEstyle Cohort Twente-1
(DIALECT-1). The study population and study proce-
dures of DIALECT-1 have been described previously17.
DIALECT is an observational cohort study in patients
with type 2 diabetes mellitus, which was designed to study
associations between lifestyle habits and clinical out-
comes. The study has been approved by local institutional
review boards (METC-Twente, NL57219.044.16; METC-
Groningen, 1009.68020), is registered in the Netherlands
Trial Register (NTR trial code 5855), and is performed
according to the guidelines of good clinical practice and
the declaration of Helsinki as revised in 2008. All parti-
cipants signed an informed consent form before partici-
pation. The reporting of the study conforms to the
STROBE statement18.
Setting
Between September 2009 and January 2016, a total of
450 high-risk type 2 diabetes patients were included in
DIALECT-1, the ﬂowchart of inclusion was previously
described17. DIALECT-1 was performed in the outpatient
clinic internal medicine of the Ziekenhuisgroep Twente
(ZGT) Hospital, Almelo and Hengelo, the Netherlands.
The ZGT hospital is a secondary care center for diabetes
treatment. In the Netherlands, referral criteria to second-
ary health care are as follows: inability to achieve adequate
glycemic control with oral antidiabetic drugs or a standard
insulin regimen, overt nephropathy (macroalbuminuria
and/or estimated glomerular ﬁltration rate below 60ml/
min), or multiple cardiovascular complications.
Participants
All patients, aged 18+ years, visiting the internal
medicine outpatient clinic for type 2 diabetes mellitus
treatment were eligible for the study. Exclusion criteria
were inability to understand the informed consent pro-
cedure, insufﬁcient command of the Dutch language, or
renal replacement therapy. Eligible patients were selected
from the electronic patient ﬁle and contacted by phone.
Variables
At the clinic, sociodemographic characteristics, medical
history, lifestyle behaviors, and current medications were
recorded and anthropometric dimensions were measured
using standard procedures. In clinical practice, upon
initiation of statin therapy, nutraceutical use is extensively
discussed as an alternative option to reduce LDLc, and
thereafter is recorded in the electronic patient ﬁle. As we
found no to very few mentions ( < 1%) of nutraceutical use
in the patients’ ﬁles, nutraceutical use was not included in
this study. Medical history was additionally reviewed in
the hospital electronic patient ﬁles on three different
occasions, by three different physician researchers. Mac-
rovascular disease was deﬁned as the presence of either
coronary heart disease (CHD), cerebrovascular disease, or
peripheral artery disease. CHD was deﬁned as the pre-
sence of one of the following in medical history: physician
diagnosed unstable angina pectoris, myocardial infarction,
percutaneous coronary intervention, or coronary artery
bypass graft. Cerebrovascular disease was deﬁned as a
history of transient ischemic attack or cerebrovascular
accident. Peripheral artery disease was deﬁned as the
presence of one of the following in medical history: pro-
ven artery disease by angiogram or magnetic resonance
angiogram, percutaneous transluminal angioplasty, or
peripheral artery bypass graft.
Blood pressure was measured in a supine position by an
automated device (Dinamap®; GE Medical Systems, Mil-
waukee, WI) for 15min with a 1 min interval. The mean
systolic and diastolic pressure of the ﬁnal three mea-
surements was used for further analysis.
Physical activity was assessed using the Short QUes-
tionnaire to ASses Health enhancing physical activity
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questionnaire, which was previously validated and is
commonly used in the Netherlands for population
research19. Diet was assessed using a semi-quantitative
Food Frequency Questionnaire (FFQ) inquiring about
intake of 177 items during the last month, taking seasonal
variations into account20. The FFQ was developed and
validated at the Wageningen University and has been
updated several times20, 21. For each item, the frequency
was recorded in times per day, week, or month. The
number of servings was expressed in natural units (e.g.,
slice of bread or apple) or household measures (e.g., cup
or spoon). Both questionnaires were self-administered
and ﬁlled out at home. The ﬁlled in questionnaires were
checked for completeness by a trained researcher, and
inconsistent answers were veriﬁed with the patients.
Dietary data were converted into daily nutrient intake
using the Dutch Food Composition Table of 201322.
Patients with a very low ( < 500 kcal/day) or very high ( >
6000 kcal/day) were excluded from the analyses, which
was based on habitual caloric intake in the Netherlands23.
Blood was drawn from venipuncture in a non-fasting
state, for measurement of cholesterol and other variables
relevant for diabetes. Total high-density lipoprotein
(HDL) cholesterol and triglycerides were determined with
the enzymatic colorimetric method using routine
laboratory procedures with a Clinical Chemistry Analyzer
and Immunochemistry Analyzer (COBAS 8000; Roche
Diagnostics GmbH, Mannheim, Germany). LDL choles-
terol was calculated using the Friedewald formula (only if
triglycerides < 4.5 mmol/l). 24 h urine collections were
performed as prescribed previously17.
Targets and deﬁnitions
The treatment target for LDLc was set as ≤ 2.5 mmol/l,
according to the Dutch guidelines for cardiovascular risk
management in type 2 diabetes mellitus used by inter-
nists9. As the European guideline for CVD prevention
deﬁnes the target LDLc at < 1.8 mmol/l8 for patients with
a very high risk (97% of our population), and this target is
used by Dutch cardiologists, we also studied how well this
target was reached.
According to the general Dutch guidelines for cardio-
vascular risk management used by internists, statin therapy
is indicated when LDLc is > 2.5mmol/l and the 10-year risk
of CVD is ≥ 20%, or the risk is 10-20% and there is an
additional risk factor (i.e. family member with CVD, phy-
sical inactivity, BMI ≥ 30, or reduced renal function)9. The
10-year risk is determined using age, smoking status, sys-
tolic blood pressure, and the total cholesterol/HDLc ratio.
In type 2 diabetes mellitus patients, 15 years should be
added to the patients’ age before calculating the risk. The
ﬁrst treatment step is simvastatin 40mg/day, followed by
atorvastatin 20–80mg/day or rosuvastatin 1–40mg/day,
according to maximal tolerated doses and LDLc response.
In our study, medium intensity statin treatment was
deﬁned as follows: simvastatin 20–40mg/day, atorvastatin
10–20 mg/day, rosuvastatin 5 mg/day, and pravastatin
40–80 mg/day24. Lower and higher prescribed dosages of
the abovementioned statins were deﬁned as low-intensity
and high-intensity statin treatment, respectively.
General lifestyle recommendations were BMI ≤ 25 kg/
m2 and smoking cessation9. The recommendation for
physical activity was at least 5 days per week 30 min of
moderate–vigorous exercise (such as cycling, brisk walk-
ing, and gardening)9. Dietary recommendations were
derived from the Dutch dietary guidelines 2015 published
by the Health Council of the Netherlands25, which are
also adopted by the Dutch Diabetes Federation and used
in clinical practice by dieticians treating diabetes
patients26. In short, the recommended intakes were as
follows: vegetables ≥ 200 g/day; fruits ≥ 200 g/day; whole-
grain products ≥ 90 g/day; legumes ≥ 1 portion/week;
unsalted nuts ≥ 15 g/day; low-fat dairy 2–3 portions/day
(including milk or yoghurt); ﬁsh ≥ 1 portion/week; ﬂack or
green tea ≥ 3 cups/day; use soft margarines, liquid cooking
fats and vegetable oils instead of butter or hard margar-
ines and cooking fats; replace unﬁltered coffee by ﬁltered
coffee; red meat ≤ 45 g/day; no processed meat; no con-
sumption of sweetened beverages and fruit juices; alco-
hol ≤ 1 unit/day; sodium ≤ 2.3 g/day. As data on whether
consumed grains were wholegrain or reﬁned and data on
whether consumed coffee was ﬁltered or unﬁltered were
not available from the FFQ used in our study, these
components were not analyzed here. Recommended daily
legume and ﬁsh intake was calculated by dividing one
portion size (60 g) by 7 and rounding up to 10 g/day. As
the FFQ did not distinguish between salted and unsalted
nuts, and type of tea, total nut intake, and total tea intake,
respectively, were used in our calculations. Data on diet-
ary sodium intake was derived from the 24 h urinary
sodium excretion17.
Statistics
All statistical analyses were performed using Statistical
Package for the Social Sciences (IBM, Chicago, IL, USA),
version 22.0. Normality of data was assessed by visually
inspecting the frequency histograms. Normally dis-
tributed data were presented as mean ± SD. Skewed
variables were expressed as median (interquartile range).
Dichotomous variables were presented in number and
percentage. Cases with missing data were excluded from
the respective analyses. To describe characteristics of
patients who had achieved different LDLc values, the
population was divided in three groups according to
LDLc < 1.8 mmol/l, 1.8–2.5 mmol/l, and > 2.5 mmol/l.
Differences between the groups were tested using one-
way analysis of variance (normally distributed),
Kruskal–Wallis (skewed), or χ2-test (categorical).




For the current study, plasma LDLc concentrations
were available in 428 patients of the total 450 patients
included in DIALECT-1. Baseline characteristics are
shown in Table 1. Mean age of patients was 63 ± 9 years
and 58% of patients were men. The median diabetes
duration was 11 (7–18) years, mean HbA1c was 57 ± 12
mmol/mol (7.4 ± 3.2%). Most patients were overweight or
obese, mean BMI was 32.0 ± 6.3 kg/m2, and 6% of patients
had a BMI < 25 kg/m2. The majority of patients had one
or more complications: 65% of patients had microvascular
disease, with nephropathy being the most frequent (42%
of all patients), and 35% had macrovascular disease.
Mean LDLc in the whole population was 2.0 ± 0.8mmol/
l. In total, 334 patients (78%) achieved the target LDLc ≤
2.5mmol/l, among which 184 patients (43% of the total
population) achieved an LDLc < 1.8mmol/l (Table 1).
Patients with LDLc ≤ 2.5mmol/l had a longer diabetes
duration (P= 0.006) and more often used insulin (P=
0.02). Furthermore, patients who were on target LDLc ≤
2.5mmol/l more often had retinopathy (P= 0.001).
Pharmacological lipid-lowering therapy and LDLc target
achievement
Of all patients, 76% were on current statin therapy
(Table 1). The most prevalent reasons for non-treatment
were “not indicated according to guideline” and “pre-
viously reported side-effects/patient preference” (both 8%
of the total population). In 7% of patients the reason for
not using a statin was not documented in the patient ﬁle
and there was no documentation of previous statin use.
Of the 88 patients not on statin therapy, and with an
indication for lipid-lowering therapy (LLT), 15 patients
used ezetimibe and 6 patients used ﬁbrates.
Of patients on target LDLc ( ≤ 2.5 mmol/l), 83% used
statins, whereas 41% of patients with an LDLc > 2.5
mmol//l used statins. High-intensity statin treatment was
the most prevalent in patients with a LDLc < 1.8 mmol/l
(23%) versus 13% in those with LDLc 1.8–2.5 mmol/l and
8% in those with LDLc > 2.5 mmol/l (Fig. 1). Of patients
who did not achieve the target LDLc of ≤ 2.5 mmol/l, 46%
did not use any LLT, whereas 5% used low-intensity and
28% used moderate-intensity statin treatment. Of the 54
non-statin users in the LDLc > 2.5 mmol/l group, 24
patients experienced side effects or had a personal pre-
ference to avoid statins, and in 23 patients the reason for
not using statins was not documented.
Lifestyle and LDLc target achievement
Adherence to general lifestyle guidelines was low in the
overall population and was not different between the
LDLc target groups (Table 1). In the overall population,
6% had a BMI ≤ 25 kg/m2 and 59% had physical activity as
recommended. Smoking guidelines were followed rela-
tively well, as 83% were either non-smokers or former
smokers.
The mean total kilocaloric (kcal) intake per day was
1922 ± 636 kcal/day and was not different between the
LDLc target groups (Table 1). There were no differences
in absolute intake of dietary products among the LDLc
groups. Median vegetable intake was 98 [57–136] g/day
and median fruit intake was 123 [66–227] g/day.
Adherence to dietary guidelines was low in the whole
population and there were no differences between the
LDLc target groups (Fig. 2). Only 7% of the population
consumed ≥ 200 g vegetables per day, whereas 28% con-
sumed ≥ 200 g fruit per day. Furthermore, 59% of the
population consumed legumes once weekly, 14% ate ≥ 15
g nuts per day, and 19% consumed 2–3 portions of low-fat
dairy per day. Fish intake was as recommended in 36% of
the population and 8% drank tea as recommended.
Adherence to fats and oils intake was reasonably well with
66%. In regard to meat consumption, 12% did not eat
more red meat than recommended and 2% ate no pro-
cessed meats. Alcohol intake was one unit per day or less
in 71%, and 34% drank no sweetened beverages. Sodium
intake was below 2.3 g/day in 12% of the population.
Discussion
In this real-life study in type 2 diabetes mellitus with
high cardiovascular risk, the target LDLc of ≤ 2.5 mmol/l
is reached in three quarters of the patients. Statin use was
markedly more frequent and statin dosage was higher in
patients who had achieved the LDLc target. Therefore,
pharmacological treatment with statins, used in approxi-
mately three quarters of patients, is the most important
part of LDLc lowering treatment in routine clinical
practice. In contrast, adherence to lifestyle guidelines was
poor in the whole study population, especially on BMI
and intake of vegetables, legumes, nuts, red and processed
meat, tea, and sodium.
Overall, the data illustrate that statin therapy is well
incorporated in routine diabetes care and is an effective
tool to reach target LDLc in the real-world setting of type
2 diabetes mellitus treatment. The percentage of ade-
quately controlled LDLc reported here is somewhat
higher than found in other studies. A previous study
demonstrated LDLc target achievement in 56% of type 2
diabetes mellitus patients treated in the primary health
care setting in the Netherlands11. In the large European
EUROASPIRE study, LDLc targets attainment was
reported in 33% of patients12. De Cosmo at al.10 reported
adequately controlled LDLc in 51% of patients with dia-
betes and chronic kidney disease. The high percentage of
patients on target for LDLc we found illustrates that LLT
is well incorporated in routine secondary clinical care of
high risk type 2 diabetes mellitus patients. The target
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LDLc was more often reached by patients with more
serious disease, as indicated by a longer duration of type 2
diabetes mellitus, more frequent insulin use, and higher
prevalence of microvascular complications. This suggests
that a higher urgency for aggressive LDLc lowering
treatment is experienced in patients with a higher grade of
comorbidity.
In the patients who were not on statin treatment, one-
third had no strict indication for LLT, one-third had
previously experienced side effects, and in roughly one-
third, the reason for not using a statin was not docu-
mented. Possibly, the latter subgroup consists of indivi-
duals with a preference of not using a statin, either based
on general perceptions or because of side-effects in the
past (this was not documented in the patient ﬁles). The
chance that the option of prescribing a statin has been
overlooked is negligible, taking into account the disease
duration, frequent contact with sequential physicians and
diabetes nurses, and a system in which also pharmacists
verify adherence to guidelines.
Adherence to dietary recommendations was low in our
population of type 2 diabetes mellitus patients. It should
be noted that the majority of ﬁndings on dietary intake
reported here were not different from dietary intake in the
general Dutch population as reported by the National
Institute for Public Health27–29. The general population
had a slightly lower intake of fruits (113 vs. 123 g/day in
DIALECT), legumes (5 vs. 12 g/day in DIALECT), red
meat (79 vs. 91 g/day in DIALECT), and low-fat dairy (180
vs. 213 g/day in DIALECT). Intake of processed meat (50
vs. 49 g/day in DIALECT) and ﬁsh (18 vs. 10 g/day in
DIALECT) was comparable. Intake of vegetable was
higher in the general population, 139 g/day vs. 98 g/day in
DIALECT. Interestingly, intake of sweetened beverages
was substantially higher in the general population (336 vs.
27 g/day in DIALECT). The difference in intake of
sweetened beverages possibly reﬂect the effect of dietary
counselling in diabetes patients. In conclusion, it is
important to recognize that non-adherence to dietary
guidelines is not a problem speciﬁc for type 2 diabetes
mellitus patients, but is a population-wide phenomenon.
It should be noted that the LDLc target in Dutch sec-
ondary care is deﬁned as ≤ 2.5 mmol/l, both for high-risk
and very high-risk patients9. This is different from the
European guidelines, where the LDLc target is < 1.8
mmol/l for very high-risk patients (97% of our popula-
tion)8. When using European guidelines, target achieve-
ment was somewhat lower (43%). However, when using
these guidelines, results of analyses on where treatment
opportunities lie to improve target achievement were
similar: in patients not on target, high intensity statin use
was infrequent ( < 15%) and adherence to lifestyle guide-
line adherence was low in all LDLc groups.
On a side note, we found a relatively high grade of
adherence to the recommendation for physical activity
(59%), in the general Dutch population this number was
54% in 201530. In a systematic review, correlations
between subjectively and objectively measured physical
activity were weak to moderate31. This poses the question
whether the compliance to the recommendation we
report here is an accurate reﬂection of the actual physical
activity of our population.
This study has several strengths. The integration of
pharmacological and lifestyle parameters collected in a real-
life setting provides the best possible tool to deﬁne oppor-
tunities to improve treatment strategies in type 2 diabetes
mellitus. In addition, our study population represents a real-
life clinical setting, where inclusion bias was minimal due to
the broad inclusion criteria. A potential limitation of the
study is that venipuncture was not performed in the fasting
state8, leading to a possible overestimation of serum tri-
glycerides and therefore underestimation of LDLc levels.
However, serum triglycerides were not higher than expec-
ted and therefore we estimate that this effect was minimal.
In addition, the use of the FFQs might lead to under-
estimation of intake of unhealthy products in dietary intake.
Nevertheless, there are currently no better methods for
registration of dietary habits in a study with this size. Lastly,
the cross-sectional design only allows to study associations,
and not causality. Future prospective studies are necessary
to evaluate the effects of increasing pharmacological treat-
ment and increasing lifestyle guideline adherence on LDLc
target achievement.
What should be the implications of this study? We
found that pharmacological treatment with statins was




















Fig. 1 Intensity of statin treatment in LDLc groups. There was a
signiﬁcant difference in intensity of statin use between the LDLc
groups. Medium-intensity statin treatment was deﬁned as follows:
simvastatin 20-40 mg/day, atorvastatin 10-20 mg/day, rosuvastatin 5
mg/day, and pravastatin 40-80 mg/day. Lower and higher prescribed
statin dosages were deﬁned as low intensity and high intensity,
respectively
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target. Therefore, in patients who are not on target LDLc,
the ﬁrst step could be to explore the opportunities to
either start or intensify statin treatment. As opposed to
blood pressure management in this cohort, where therapy
resistance is an issue in roughly 40% of the patients not on
target blood pressure17, our data suggest that resistance to
statin treatment is less common. In those with an LDLc
not on target, only 8% were on high-intensity statin
treatment. High-intensity statin treatment can reduce
LDLc by 40–60%, vs. a 20–30% reduction on low-intensity
treatment32. Therefore, intensifying statin treatment,
either by increasing the dose, or by switching to a more
potent compound, could be an option in a large subset of
patients not on target. Furthermore, adherence to therapy
should be addressed. Relatively low adherence to statin
therapy has been previously reported33–35, especially after
negative reports on statins by the mainstream media36, 37,
rendering it worthwhile to investigate whether prescribed
statins are actually ingested by the patients. Unfortu-
nately, such data were not available here. It should be
noted that statin treatment efﬁcacy can vary considerably
per individual, in literature a range of 5–70% LDLc
reduction in different individuals is reported38, 39. Statin
treatment resistance, i.e., not achieving LDLc target,
despite high-intensity statin treatment, has been asso-
ciated with black racial ancestry, polymorphisms in genes
affecting statin pharmacodynamics and pharmacokinetics,
smoking, inﬂammation, and HIV infection40. Certain
drugs may also reduce statin effectiveness by reducing
bioavailability (i.e., bile acid sequestrants) or increasing
statin metabolism (i.e., rifampicin). Nutraceuticals, which
sometimes are used in the general population, might also
inﬂuence LDLc target achievement; however, few studies
have been performed on the interaction between statin
use and nutraceuticals, and therefore the effect of nutra-
ceuticals statin efﬁcacy remains unclear41. In addition,
clinical conditions that increase cholesterol levels, such as
hypothyroidism, should also be reviewed. However, in a
real-life setting, LDLc target non-achievement, despite
statin treatment, can most often be attributed to treatment
non-adherence rather than treatment resistance42, 43.
For patients who fail to reach their LDLc target, there are
alternative pharmacological options to reduce LDLc. First,
in patients who do not achieve the target LDLc despite
maximum-tolerated dose statin use, ezetimibe therapy
should be considered8, 44. We found that only a quarter of
not on target patients used ezetimibe, with or without
concurrent statin use, and therefore ezetimibe therapy
could be increased. In the case of mixed dyslipidemia (i.e.,
high LDLc and high triglycerides), ﬁbrate therapy, which
was used by 8% of patients not on LDLc target in this
population, could also be considered45. When both
maximum-tolerated statin use and ezetimibe are insufﬁ-
cient, the relatively new drug class of PCSK9 inhibitors (not
used in this population) has the potential to reduce LDLc
by 32–71%, depending on the used dosage46, 47. In addi-
tion, glucagon-like peptide-1 (GLP-1) analogs, which
improve glycemic regulation, body weight, and blood
pressure in type 2 diabetes mellitus, have also been shown
to reduce LDLc and triglycerides, and increase HDLc48–50.
Moreover, GLP-1 analogs have a favorable effect on total
cardiovascular risk: in the recent LEADER trial, cardio-
vascular death was 22% lower in type 2 diabetes mellitus
patients treated with liraglutide, compared to placebo-
treated patients51. Therefore, the use of GLP-1 analogs in
clinical practice should not be overlooked, especially in
those with poor glycemic regulation in combination with
obesity, hypertension, or dyslipidemia52.
Alternatively, especially in the patients that have a
personal preference not to use statins or are intolerant to
statins, lifestyle intervention could be a worthwhile option
to improve LDLc and improve general cardiovascular risk
management. With respect to diet, one could consider to
focus on increasing the intake of vegetables and legumes,
and reducing the intake of red and processed meat. It has









































Fig. 2 Adherence to dietary guidelines on nutritional intake. There were no differences in adherence rates between the LDLc target groups
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dietary changes can reduce LDLc by 13–30%53–55. In a
post-hoc analyses of the Alpha Omega Trial, in which the
effect of omega 3 fatty acid supplementation on cardio-
vascular outcomes was studied in post-myocardial
infarction patients, a beneﬁcial effect was shown in
those not on current statin treatment56. It should be
noted that little data is available on the extent of LDLc
reduction through dietary changes in patients already on
statin treatment. Stakeholders of nutritional research in
the Netherlands have hypothesized that the high efﬁcacy
of pharmacological therapy is one of the reasons that
lifestyle intervention is less emphasized in clinical care57.
This is supported by our ﬁnding that statins, and not
lifestyle, are the main determinants of LDLc control.
Nevertheless, adopting a healthy lifestyle has pleiotropic
effects not only on cholesterol, but also on other cardio-
vascular risk factors such as obesity, blood pressure, and
insulin resistance, for which treatment resistance is a
growing concern58–63. For example, a recent meta-
analysis of 39 studies has shown that physical exercise
can reduce LDLc and improve insulin sensitivity64, espe-
cially in obese subjects. However, adherence to dietary
guidelines on these compounds is low in the overall
population, illustrating that community intervention
might be more appropriate, then just targeting type 2
diabetes mellitus patients. In the meantime, focus should
be placed to promote a healthy diet and lifestyle in
patients with type 2 diabetes mellitus.
Conclusion
In this population of high-risk type 2 diabetes mellitus
patients in a real-world secondary health care, the LDLc
target is achieved by the majority of the population. High-
intensity statin treatment was infrequent in patient who did
not achieve the LDLc target; therefore, a good opportunity
to improve LDLc target achievement could be to put as
many as possible patients on appropriate dose of statins.
Nevertheless, adherence to lifestyle and dietary recom-
mendation is low, especially on BMI and intake of vege-
tables, legumes, nuts, red and processed meat, tea, and
sodium. Therefore, the focus on lifestyle intervention
remains of great importance, because of multiple beneﬁcial
effects on obesity, blood pressure, and insulin resistance.
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